ANAB
AnaptysBio Inc
NASDAQ: ANAB · HEALTHCARE · BIOTECHNOLOGY
$65.73
+5.44% today
Updated 2026-04-30
Market cap
$1.81B
P/E ratio
—
P/S ratio
7.73x
EPS (TTM)
$-0.46
Dividend yield
—
52W range
$11 – $72
Volume
0.6M
AnaptysBio Inc (ANAB) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-5.64%
Operating margin
61.80%
ROE
-24.50%
ROA
7.06%
Debt/equity
-11.78x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $5.48M | $-5.54M | -60.86% | -96.43% | -101.13% |
| 2014 | $15.84M | $232000.00 | 45.61% | 30.75% | 1.46% |
| 2015 | $17.57M | $-5.41M | 1.52% | -18.91% | -30.76% |
| 2016 | $16.68M | $-4.26M | 7.58% | -18.13% | -25.53% |
| 2017 | $10.00M | $-30.07M | -194.43% | -287.81% | -300.70% |
| 2018 | $5.00M | $-61.66M | -1,023.92% | -1,334.44% | -1,233.12% |
| 2019 | $8.00M | $-97.34M | -1,141.73% | -1,342.90% | -1,216.70% |
| 2020 | $75.00M | $-19.93M | -6.70% | -31.84% | -26.57% |
| 2021 | $63.17M | $-57.80M | -55.91% | -89.93% | -91.49% |
| 2022 | $10.29M | $-128.72M | -763.21% | -1,119.41% | -1,251.33% |
| 2023 | $17.16M | $-163.62M | -671.01% | -958.27% | -953.66% |
| 2024 | $91.28M | $-145.23M | -79.49% | -125.93% | -159.10% |
| 2025 | $234.60M | $-13.23M | 98.97% | 20.42% | -5.64% |